Register entry
- Registered sites
- 0
- Active NDC listings
- 24
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
2424 active NDC listings: 24 plasma derivative. By marketing category: BLA 24.
| Dosage form | NDCs |
|---|---|
| solution | 11 |
| kit | 9 |
| powder, for solution | 4 |
| Route | NDCs |
|---|---|
| intravenous | 23 |
| subcutaneous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| octapharma usa inc | 24 |
Catalogue
Marketed products
24| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Albumin (Human) | Albumin Human | solution, intravenous | 68982-623BLA |
| Albumin (Human) | Albumin Human | solution, intravenous | 68982-633BLA |
| Albumin (Human) | Albumin Human | solution, intravenous | 68982-643BLA |
| Balfaxar | Prothrombin Complex Concentrate (Human) | powder, for solution, intravenous | 68982-261BLA |
| Cutaquig | immunoglobulin G | solution, subcutaneous | 68982-810BLA |
| Fibryga | Fibrinogen (Human) | kit, intravenous | 68982-347BLA |
| Fibryga | Fibrinogen (Human) | powder, for solution, intravenous | 68982-349BLA |
| Fibryga | Fibrinogen (Human) | powder, for solution, intravenous | 68982-350BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-139BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-141BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-143BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-145BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-147BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-149BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-151BLA |
| NUWIQ | Antihemophilic Factor (Recombinant) | kit, intravenous | 68982-153BLA |
| Octagam Immune Globulin (Human) | Immune Globulin | solution, intravenous | 68982-840BLA |
| Octagam Immune Globulin (Human) | Immune Globulin | solution, intravenous | 68982-850BLA |
| Octaplas | human plasma proteins | solution, intravenous | 68982-952BLA |
| Octaplas | human plasma proteins | solution, intravenous | 68982-953BLA |
| Octaplas | human plasma proteins | solution, intravenous | 68982-954BLA |
| Octaplas | human plasma proteins | solution, intravenous | 68982-955BLA |
| Panzyga | immune globulin intravenous (human) | solution, intravenous | 68982-822BLA |
| Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human) | von Willebrand Factor/Coagulation Factor VIII Complex (Human) | powder, for solution, intravenous | 68982-182BLA |
Compare
Other companies listing antihemophilic factor (recombinant)
- Bayer Healthcare Manufacturing Srl13 sites · 360 NDC
- Takeda Pharmaceuticals U.S.A., Inc.7 sites · 226 NDC
Enquiry
Common questions
- Is Octapharma USA Inc FDA approved?
- Octapharma USA Inc holds no registered establishment of its own; 24 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Octapharma USA Inc make?
- 24 products are listed under Octapharma USA Inc in the openFDA NDC Directory, most often as solution; kit; powder, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.